MedTrace Logo

Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost

NCT04743622 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2021-02-08

No results posted yet for this study

Summary

Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Study

Conditions

Interventions

DRUG

Monoprost

preservative-free latanoprost 1 drop once a day for 12 weeks to target eyes

DRUG

Xalatan

preserved latanoprost 1 drop once a day for 12 weeks to target eyes

Sponsors & Collaborators

  • Samil Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • CHA University

    lead OTHER

Principal Investigators

  • Seungsoo Rho, MD, PhD · CHA Bundang Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-30
Primary Completion
2020-06-23
Completion
2020-09-13

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04743622 on ClinicalTrials.gov